

Implementing a Tribally-Engaged Lung Cancer Screening Program in Rural Oklahoma (Update)

Zsolt Nagykalai, PhD; Mark Doescher, MD; Dorothy Rhoades, MD, MPH; Kathleen Dwyer, PhD, RN; Ann Chou, PhD, MPH
Brook McCann, RN; Natassia Zink, RN; Martha Howze, RN

*In partnership with the
Choctaw Nation of Oklahoma*



DISCLOSURES

- Consultant for: **None**
- Speaker's Bureau for: **None**
- Grant/Research support from: **NCI R01CA225439**
- Stockholder in: **None**
- Honoraria from: **None**
- Employee of: **University of Oklahoma HSC**

I will not discuss off label use and/or investigational use in my presentation. Views expressed are my own and do not necessarily reflect those of my institution, the Choctaw Nation of Oklahoma or the funding agency.



Learning Objectives

- ❖ Through a pilot study example demonstrate how **evidence can be translated into clinical practice** for implementing a low-dose CT lung cancer screening (LCS) program in a rural/tribal community
- ❖ Explore the components and steps of **implementing** an LCS program that may overcome some of the **barriers** to increasing LCS rates in rural/tribal health systems
- ❖ Discuss how lessons learned from our pilot study may help attendees **facilitate the dissemination** of an LCS program in their organization



TEALS Study Background & Aims

Lung cancer screening (LCS) with low-dose computed tomography is a [grade-B USPSTF](#) recommendation (2013 → 2021) and reduces mortality by 20%. Implementation of LCS has rarely been studied [in American Indian](#) and Alaska Native (AI/AN) communities, many of which are at [increased risk](#) of lung cancer.

We initiated the Tribally Engaged Approaches to Lung Screening (TEALS) study in 2019 to co-design and test a tribal [community-engaged LCS implementation](#) program:

- ❖ **Aim 1**: Identify individual, community, cultural, health system [barriers & facilitators](#) that affect LCS implementation in the Choctaw Nation;
- ❖ **Aim 2**: Use community-engagement processes to co-design a [tailored TEALS intervention](#), which features LCS care coordinators embedded within the CNHSA healthcare delivery system;
- ❖ **Aim 3**: Measure the [impact of the LCS program](#) in a clinical trial, assessing process outcomes at the individual and care delivery system level;
- ❖ **Aim 4**: [Disseminate the LCS program](#) to other health systems.



TEALS Community Partnership

- ❖ TEALS is based on a Community-Engaged Research (CEnR) approach supported by an academic-tribal research subcontract
- ❖ TEALS engages 8 primary care centers of the Choctaw Nation Health Services Authority (CNHSA) in Southeast Oklahoma (2 LDCT scanner sites: Talihina & Durant)
- ❖ University of Oklahoma Health Sciences Center and the Stephenson Cancer



Choctaw Nation
Health Services



Choctaw Nation of Oklahoma
primary care sites in SE OK




TEALS Study Design & Population

- Year 1:** **Planning** and program co-development with our partners using community-engaged research
- Year 2:** **Pilot** implementation study in 2 CNHSA primary care centers
- Years 3-4:** Pair-matched, **cluster RCT** in 6 CNHSA primary care centers
- Year 5:** **Dissemination** of results and facilitating implementations
- ❖ Enrollment: Patients seen in selected practices ($N_{\text{total}} = 268$), who meet LCS criteria and clinicians/staff/leadership ($N_{\text{total}} \sim 50$) from clinic sites
 - ❖ Quality improvement and implementation support for LCS across all CNHSA clinic sites



TEALS Planning Phase (Year-1)

Creating a tribal community-centered **study protocol** and obtaining multiple Institutional Review Board (IRB) approvals



Establishing a **Community Advisory Board (CAB)**, representing key LCS constituents within the CNHSA

The CAB advises investigators on the **study planning** process and develops a Choctaw Nation-tailored LCS **patient decision-aid** for system-wide use



Establishing and operating a **Scientific Advisory Board (SAB)** of 3 national LCS experts and 8 key study personnel

Providing LCS care **coordinator training** through the Stephenson Cancer Center in Oklahoma City




Mapping and analyzing the LCS care delivery process with the help of a trained primary care practice facilitator



TEALS Pilot Study Patient Care Path

- ❖ Two mid-size primary care practice centers were selected to serve as **implementation pilot sites** (N=57 patients)
- ❖ The LCS intervention was centered on 1.5 FTE health system-wide **lung cancer screening coordinators** (LCCs) both at the clinic sites and at the health system level
- ❖ LCCs used OMNI to track services (**patient registry**)



TEALS Pilot Study Measures

Measures & Timing	Description of Measures	Data Sources and Collection Methods	N (sample)
<u>Patient</u> measures at baseline and at 6 months	Patient demographics and socio-economic status (SES)	Practice records and short SES survey	Planned: 50/practice N=100 N=57 (actual)
	Patient attitudes toward LCS	Attitudes survey	
	Patient experience with preventive care	CAHPS PCC-10 survey	
<u>Patient</u> measures at 12 months	Patient interviews on experience and satisfaction with the LCS program	Interviews with LCS completers and non-completers	10 per practice 20 total
<u>Practice</u> measures at baseline and 12 mos	Practice readiness for preventive care improvement	CPCQ survey	3 per practice 6 total
<u>System</u> measures at 12 months	System-level experience with LCS program, decision making factors, feedback	Interviews with CNHSA leadership	10 total



TEALS Pilot Patient Population Statistics

Demographic Characteristics	N (57)	%
Mean Age (years):	67 (55-77)	-
Sex (female):	28	49
Race :	N (57)	%
Native American/American Indian (NA/AI)	57	100
Biracial (White and NA/AI)	1	0.2
Median Annual Household Income:	N (57)	%
<\$25,000	28	49
\$25,000-\$50,000	15	26
\$50,000+	14	25
Education:	N (57)	%
High school or less	33	57
At least some college	24	43

Smoking Statistics

- ❖ **Current rate of cigarette smoking:** 66% of respondents
- ❖ **Number of cigarettes per day:** 23+/-12 (mean/SD)
- ❖ **Length of smoking:** 43+/-11 (mean/SD) years
- ❖ **Pack-years of smoking:** 46+/- 23 (mean/SD)
- ❖ **Mean quit time:** 8 years
- ❖ **Smoking cessation intervention:** 63% of LCS patients who smoked had documented intervention or f/u



TEALS Pilot Study Baseline Care Utilization

Access to Care Characteristics	Mean	Range
Number of visits in 6 months:	4.56*	1-7
Preventive Care Patterns:		
	N	%
Made an appointment for a health checkup with doctor	34	60
Up-to-date on the Following Tests/Exams:		
	N	%
Mammogram	10	18
Colonoscopy, sigmoidoscopy or stool test	17	30
CT scan to look for lung cancer	22	39

* unchanged during the study



TEALS Pilot Participation & LCS Statistics

Participation Metrics (October 2021 - June 2022)	N (57)	%
Completed baseline patient survey	56	98%
Completed post-intervention patient survey	44	79%
Participant deaths (unrelated)	1	0.02%
Lost to follow-up	12	21%
Study participation time (months)	8.6 +/- 1.8	-
Lung Cancer Screening (LCS) Metrics	N (57)	%
Up-to-date on lung cancer screening (after ~8-month intervention)	22 --> 33	39% -> 58%*
Screening result Lung-RADS 1 ("negative")	34	60%
Screening result Lung-RADS 2 ("benign appearance" nodule/s)	17	30%
Screening result Lung-RADS 3 ("probably benign" nodule/s)	3	5%
Screening result Lung-RADS 4 ("suspicious" nodule/s)	3	5%
Further evaluation of nodules	9	15%
Malignant nodules	0	0%

*p < 0.01



TEALS Pilot Patient Surveys (Pre & Post)

- ❖ Most patients agreed that their doctors almost always/always **explain things** in a way that was easy to understand (Likert scale mean = 5.42 [1-6]; *no change*)
- ❖ Most patients agreed that their doctors almost always or always **spend enough time** with them (Likert scale mean = 5.39 [1-6]; *no change*)
- ❖ 65% agreed that they may get lung cancer during their lifetime, but that “lung scans” will **aid early detection** and reduce risk (*no change*)

Patient Knowledge & Attitudes About LCS (Pre-Post)	N (56-44)	%
Addressing patient recall of offering choices for their care	46/56 – 44/44	82% – 100%*
Discussing specific care treatments with the clinician	50/56 – 44/44	89% – 100%*
Offering a CT scan to look for lung cancer	31/56 – 36/44	56% – 81%*
Patient awareness about lung cancer screening	32/56 – 36/44	58% – 81%*
Patient’s belief that no one had lung cancer in the family	7/56 – 15/44	13% – 35%*

*p < 0.04 (pre-post)



TEALS Pilot Qualitative Patient Feedback

Semi-structured patient interviews with screening completers (10) & non-completers (10)

Contextual Factors in the Clinical Environment

- ❖ Primary care [clinician does not bring up LCS](#) (the most frequently noted barrier!)
- ❖ Use of (culturally) tailored [decision-support materials](#) and [patient education](#) are often lacking

Practical Barriers to Screening

- ❖ [Past diagnostic chest CTs](#), “muck up” decision-process for screening eligibility
- ❖ [Long distance](#) travel and [gaps in transportation](#) to LCS sites (major barrier in rural areas)
- ❖ [Work absenteeism](#) and [coverage gaps](#) for screening or follow-up services
- ❖ [Confusion](#) about the nature of the appointment leading to missed appointments (education!)

Characteristics that Influence Individual Decision Making

- ❖ [Personal motivation](#) to ‘be there’ for family/children (survival or ability to function as needed)
- ❖ [Family history](#) of previous cancers (bad experiences and family stories)
- ❖ [Ease of scheduling](#) appointments and following LCS referrals
- ❖ [Shame/stigma](#) or [preferred not to know](#) the results of screening (“*You did this to yourself...*”)



TEALS Program Implementation Components

- ❖ Large banners offering LDCT screening in participating clinics
- ❖ 1.5 FTE lung cancer **screening coordinators**
- ❖ Tribally-tailored education/SDM **support materials**
- ❖ **Academic detailing** in all primary care practices
- ❖ **Practice facilitation** in all primary care practices
- ❖ Screening **registry** and data management support
- ❖ Smoking **cessation service** improvements
- ❖ Some **transportation support** (e.g., tribal vehicles)
- ❖ Systematic **appointment reminders**
- ❖ Eligibility **triage tool** (on iPads)
- ❖ Community **advisory board**
- ❖ Scientific advisory board
- ❖ Clinician “**best practices**”
- ❖ Peer clinician **champion** support



More Lessons: Optimized LCS Process

- ❖ **Step 1**: Improving [smoking history assessment](#) and documentation (to determine pack years)
- ❖ **Step 2**: Implementing screening [conversation triggers](#) (regular care and population health)
- ❖ **Step 3**: Building a preventive [care coordination](#) function (coordinator/navigator and screening registry)
- ❖ **Step 4**: Instituting an LCS [shared decision-making](#) process (in-clinic or post-visit nurse calls)
- ❖ **Step 5**: Deploying a robust patient [follow-up process](#)
- ❖ **Step 6**: Linking LCS to [smoking cessation](#) services



Lessons Learned from the TEALS Pilot

- ❖ A community-engaged, multi-component, and multi-level program **can significantly improve** LCS rates in rural and tribal health systems
- ❖ A key feature of TEALS is a **centralized LCS coordination** service supported by a population-based screening registry
- ❖ Ongoing **community stakeholder participation** and community-tailoring of the intervention approach greatly contributed to the success of TEALS
- ❖ If supported by the findings of our larger clinical trial, TEALS holds **promise for dissemination** to other high-need primary care settings



TEALS: Acknowledgements



TEALS is supported by a National Cancer Institute grant (R01CA225439). The authors have no conflicts of interest.

We thank the Choctaw Nation Health Services Authority Community Advisory Board for their excellent support!



Questions? Comments?



Zsolt Nagykaldi, PhD

znagykal@ouhsc.edu

